Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely

A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness

Lieven Stuyver, Sija De Gendt, Caroline Van Geyt et al. · Microbiology · 2000 · 914 citations

Life Sciences, Genetics, Molecular Genetics +14

Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B

Ting‐Tsung Chang, Ching‐Lung Lai, Seung Kew Yoon et al. · Hepatology · 2010 · 586 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †

Maurizia Rossana Brunetto, F. Moriconi, Ferruccio Bonino et al. · Hepatology · 2008 · 483 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients #

Rami Moucari, Vincent Mackiewicz, Olivier Lada et al. · Hepatology · 2008 · 482 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

E. Jenny Heathcote, Patrick Marcellin, Edward Gane et al. · Gastroenterology · 2010 · 461 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13